Navigation Links
Genmab in Medical News

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

Three New Studies Initiated in Other Oncology Settings LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

...hare, from Medarex's sale of 2.5 million shares of genmab A/S ("Genmab") stock in February 2008; a non-cash ...fair market value of Medarex's equity interests in genmab and Celldex were approximately $87.4 million and a... million through the sale of 2.5 million shares of genmab A/S common stock, reducing our ownership in...

Genmab Announces 2008 First Half Year Results

... Summary: genmab Reports Results for the Six Month Period Ended Jun... COPENHAGEN, August 27 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today results for the six...th period ended June 30, 2008. During this period, genmab reported the following results: Genmab's revenue...

Medarex Announces 2008 First Quarter Financial Results

...hare, from Medarex's sale of 2.5 million shares of genmab A/S stock in February 2008, Medarex's net income f...od in 2007. In addition to the gain on the sale of genmab A/S stock, Medarex's net income for the quarter en... fair market value of Medarex's equity interest in genmab was approximately $115.6 million as of March 31, 2...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...rp. (Nasdaq: ARTC ) Endo Pharmaceuticals Hldgs. (Nasdaq: ENDP ) Fresenius Medical Care AG (XETRA: FME.DE) GEDEON RICHTER RT (XETRA: R1G1.DE) genmab A/S (Copenhagen: GEN.CO) H. LUNDBECK A/S (Copenhagen: LUN.CO) Human Genome Sciences (Nasdaq: HGSI ) Imclone Systems (Nasdaq: IMCL ) Invernes...

Medarex Announces 2007 Fourth Quarter and Year End Financial Results

...arex's sale of approximately 2.6 million shares of genmab A/S stock in February 2007, Medarex's net loss for... fair market value of Medarex's equity interest in genmab was approximately $291.2 million as of December 31... the sale of approximately 2.6 million shares of genmab A/S common stock. "We enter 2008 with great ...

Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma

... Summary: genmab has Initiated a Phase II Study of Ofatumumab in Re...EN, Denmark, December 13 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today that study centers ...evelopment and commercialization agreement between genmab and GlaxoSmithKline. "We have now expanded the o...

Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

... Summary: genmab and GSK Have Announced the Initiation of the Phase...EN, Denmark, November 20 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: ... "We are very pleased that our collaboration with genmab has progressed so that we can now move to the next...
Genmab in Medical Technology

Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio

Review Zanolimumab Program to be Discontinued and Headcount to be Reduced Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab Program to be Discontinued and the Company Will Reduce the Number of Employees COPENHAGEN, October 8 /PRNewswire-F...

Bionomics Achieves US$1 Million Milestone Payment from Genmab

ADELAIDE and COPENHAGEN, Feb. 19 /PRNewswire-FirstCall/ -- Bionomics Limited (ASX: BNO, US OTC: BMICY) today announced the successful completion of pre-clinical testing on the first of eight proteins licensed to US $2.6 billion Danish antibody company Genmab A/S (OMX: GEN), triggering a US $1 ...

New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN) announced today that the results of a Phase II study with ofatumumab (HuMax-CD20™) in patients with rheumatoid arthritis (RA) have been accepted for oral presentation at the 2007 Annual European Congress of Rheumatology (EULAR). The...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

New Data to be Presented at the European League Against Rheumatism (EULAR) Congress Demonstrates the Potential Benefit of ofatumumab in Patients With Rheumatoid Arthritis LONDON, England; PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, June 15, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline (G...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...wire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and genmab A/S [OMX: GEN] today announced that the United Sta...rs of dedicated research and collaboration between genmab and GSK." The advisory committee made its de...b is being developed under a collaboration between genmab and the GSK Oncology and BioPharm R&D Units. ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

...RNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and genmab A/S (OMX: GEN) announced today positive results fr...ly collaborating on filing submissions." genmab and GSK now expect to file a Biologics License App...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved for an...

Recruitment Completed in Ofatumumab NHL Pivotal Study

... Summary: genmab has Completed Recruitment of Patients in the Phase...COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today it has completed re...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved for sa...

Genmab Announces Upcoming Ofatumumab Studies

...AGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- genmab has announced plans to begin four studies of ofatu...lymphocytic leukemia and non-Hodgkin's lymphoma. genmab A/S (OMX: GEN) announced today plans to begin four...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved in any...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

...nt COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: ...This also represents a significant achievement for genmab as we now move toward filing of the first marketin...t and Medicine Development Leader at GSK. "GSK and genmab are collaborating on a comprehensive development p...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

...ne and cyclophosphamide to treat front line CLL. genmab A/S (OMX: GEN) announced today it has completed re...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved in any...d at any time during the treatment period. About genmab A/S ...
Genmab in Biological Technology

Passing of Genmab A/S' Annual General Meeting

COPENHAGEN, April 23 /PRNewswire-FirstCall/ -- Summary: At Genmab A/S' Annual General Meeting held today on April 23, 2008 the Annual Report for 2007 was approved, discharge was given to the Board of Directors and the Management and the year's loss was carried forward. Two members of the Board...

Medarex Announces Completion of Sale of Shares in Genmab A/S

PRINCETON, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that it has completed the sale of approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 1, 2008. Medarex...

Roche Files IND for Second Genmab Antibody

Summary: Genmab's Partner Roche has Filed an IND With the US FDA for a Genmab Antibody COPENHAGEN, August 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner Roche has filed an Investigational New Drug application (IND) with the US Fo...

Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic

Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody Developed Under the Company's Collaboration with Roche. COPENHAGEN, December 12 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that an Investigational New Drug application (IND) for a Genmab antib...

Pepscan Achieves First Milestone in Research Collaboration With Genmab

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets. Peps...

Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium

...e more reticent. They are looking at a completely different risk-reward equation." Symposium panelists also included: Annarie Lyles , Ph.D., genmab , Senior Vice President/Head of Business Development; Andrew Reaume , Ph.D., M.B.A., Melior Discovery , President/CEO; Evan Myrianthopoulos ...

Medarex Announces 2009 First Quarter Financial Results

... per share, from the sale of 2.5 million shares of genmab A/S stock in February 2008. Medarex's net loss for...fair market value of Medarex's equity interests in genmab and Celldex Therapeutics were approximately $85.3 ...4,490 67,154 Marketable securities - genmab 85,274 87,428 Inve...

Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe

...stronger" prepared in cooperation with the Danish Association of Biotechnology Industries. "Being a global biotech company founded in Denmark, genmab is proud to be part of the important Medicon Valley biotech sector. We have found the innovative climate inspiring in the process of building our late...

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

... COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- genmab A/S (OMX: GEN) announced today that three ofatumum...evelopment and commercialization agreement between genmab and GlaxoSmithKline. It is not yet approved for sale in any country. About genmab A/S ...

Medarex Announces 2008 Third Quarter Financial Results

...fair market value of Medarex's equity interests in genmab A/S and Celldex Therapeutics, Inc. were approximat... - 14,000 Marketable securities - genmab - 152,000 Other c... 72,127 79,925 Marketable securities - genmab non-current 131,704 139,165 Investm...
Other Tags
(Date:7/31/2014)... Healthpointe Medical Group, one of ... the highest standards in health and safety for ... offering Occupational Medicine Services at their ... They also accept workers’ compensation cases and referrals ... services include, but are not limited to, return-to-work ...
(Date:7/31/2014)... July 31, 2014 Healthinsurancefacts.org has ... affordable health insurance plans by comparing quotes. , ... plans, clients should consider comparing quotes. They can do ... completing a simple questionnaire. , Clients should do ... several individual health insurance policies, and each of them ...
(Date:7/31/2014)... Dallas Fit Body Boot Camp ... 3821 Ross Avenue, also in Dallas, in an effort to ... to burn fat and get in great shape fast. , ... believes that the new space will help his current members ... want as well as accommodate new members interested in joining ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... first-ever event in New York on Thursday, August 7, ... Manhattan. , Featuring keynotes by State Senator Diane ... (R-Yorktown), the event will include lunch and in-depth discussions ... and the work NCIA is doing federally to advance ...
(Date:7/31/2014)... With a busy lifestyle, it is hard to relax. World ... but to ensure their mental health is equally in check. ... right is key to your body’s health. However, I want everyone ... healthy lifestyle,” expressed Chef Ravi, owner of World Gardens Cafe. Check ... , ", 1. Stop eating lunch at your desk or taking ...
Breaking Medicine News(10 mins):Health News:Occupational Medicine Services Available at Healthpointe’s Perris Facility 2Health News:Comparing Health Insurance Quotes Can Help Clients Find Affordable Plans 2Health News:Dallas Fit Body Boot Camp Moves to New Location, Announces Grand Opening Set for Saturday August 9th 2Health News:THURSDAY, AUG 7: First-Ever National Cannabis Industry Association Event in New York Will Feature Senator Savino, Assemblyman Katz, & Industry Leaders 2Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 2Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 3Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 4
(Date:7/30/2014)... at New York University is paving the way ... in civilians and military troops exposed to poisonous ... , An article in the current issue of ... in detoxifying organophosphates, which are compounds commonly used ... was developed by NYU School of Engineering Associate ...
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
Other Contents